[18F]FDG-PET在新辅助免疫检查点阻断治疗头颈部鳞状细胞癌中准确早期识别病理缓解
在IMCISION试验中,32例II‒IVb期头颈部鳞状细胞癌患者接受新辅助纳武利尤单抗联合或不联合伊匹木单抗治疗,21例可分析[18F]FDG-PET/CT。8例缓解者的ΔMTV和ΔTLG显著低于13例非缓解者,ΔMTV或ΔTLG阈值-12.5%识别原发肿瘤缓解的准确率为95%,优于EORTC标准的86%。颈部淋巴结可见假性进展。
要点
- 原发肿瘤ΔMTV或ΔTLG≥-12.5%识别病理缓解准确率95%,优于EORTC标准86%。
- 缓解者ΔSUVmax、ΔSUVmean、ΔMTV、ΔTLG中位数均下降,显著低于非缓解者。
- 颈部淋巴结SUVmax升高者中仅48%病理证实转移,提示假性进展。
核心结论
- 基于[18F]FDG-PET的ΔMTV和ΔTLG评估原发肿瘤缓解可准确早期识别HNSCC新辅助ICB后的病理缓解,优于EORTC标准,但颈部淋巴结可见假性进展。
- [18F]FDG-PET经验证后可在未来试验中用于筛选HNSCC患者进行缓解驱动的治疗调整。
研究设计与样本
- IMCISION试验(NCT03003637)中32例II‒IVb期HNSCC患者接受新辅助纳武利尤单抗联合(n=26)或不联合(n=6)伊匹木单抗治疗(第1周和第3周),第5周手术。
- 21例患者在基线和术前接受[18F]FDG-PET/CT扫描,分析SUVmax、SUVmean、MTV和TLG。
- 主要病理缓解(MPR)和部分病理缓解(PPR)依据原发肿瘤标本残留存活肿瘤分别定义为≤10%和11-50%,淋巴结转移病理缓解单独评估。
- 2例未手术的可分析患者依据临床和MR-RECIST v.1.1判定缓解。
- 原发肿瘤达MPR、PPR或MR-RECIST缓解者定义为缓解者。
主要发现
- 8例缓解者的ΔSUVmax、ΔSUVmean、ΔMTV、ΔTLG中位数下降,显著低于13例非缓解者(P=0.05、P=0.002、P<0.001、P<0.001)。
- ΔMTV或ΔTLG至少-12.5%检测原发肿瘤缓解的准确率为95%,EORTC标准为86%。
- 原发肿瘤部位ΔTLG≥-12.5%的患者均未复发(自手术起中位随访23.0个月)。
- 5个淋巴结转移(3例患者)达PPR或MPR,SUVmax显著下降(中位-3.1,P=0.04)。
- 27个淋巴结(11例患者)SUVmax升高(中位+2.1),相应颈清扫标本中仅13个淋巴结(48%)含转移。
关键数值与推荐
- MPR定义:原发肿瘤残留存活肿瘤≤10%。
- PPR定义:原发肿瘤残留存活肿瘤11-50%。
- ΔMTV或ΔTLG至少-12.5%为识别原发肿瘤缓解的阈值。
- 原发肿瘤ΔTLG≥-12.5%的患者无复发(中位随访23.0个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the utility of [18F]FDG-PET as an imaging biomarker for pathological response early upon neoadjuvant immune checkpoint blockade (ICB) in patients with head and neck squamous cell carcinoma (HNSCC) before surgery. METHODS: In the IMCISION trial (NCT03003637), 32 patients with stage II‒IVb HNSCC were treated with neoadjuvant nivolumab with (n = 26) or without (n = 6) ipilimumab (weeks 1 and 3) before surgery (week 5). [18F]FDG-PET/CT scans were acquired at baseline and shortly before surgery in 21 patients. Images were analysed for SUVmax, SUVmean, metabolic tumour volume (MTV), and total lesion glycolysis (TLG). Major and partial pathological responses (MPR and PPR, respectively) to immunotherapy were identified based on the residual viable tumour in the resected primary tumour specimen (≤ 10% and 11-50%, respectively). Pathological response in lymph node metastases was assessed separately. Response for the 2 [18F]FDG-PET-analysable patients who did not undergo surgery was determined clinically and per MR-RECIST v.1.1. A patient with a primary tumour MPR, PPR, or primary tumour MR-RECIST-based response upon immunotherapy was called a responder. RESULTS: Median ΔSUVmax, ΔSUVmean, ΔMTV, and ΔTLG decreased in the 8 responders and were significantly lower compared to the 13 non-responders (P = 0.05, P = 0.002, P < 0.001, and P < 0.001). A ΔMTV or ΔTLG of at least - 12.5% detected a primary tumour response with 95% accuracy, compared to 86% for the EORTC criteria. None of the patients with a ΔTLG of - 12.5% or more at the primary tumour site developed a relapse (median FU 23.0 months since surgery). Lymph node metastases with a PPR or MPR (5 metastases in 3 patients) showed a significant decrease in SUVmax (median - 3.1, P = 0.04). However, a SUVmax increase (median + 2.1) was observed in 27 lymph nodes (in 11 patients), while only 13 lymph nodes (48%) contained metastases in the corresponding neck dissection specimen. CONCLUSIONS: Primary tumour response assessment using [18F]FDG-PET-based ΔMTV and ΔTLG accurately identifies pathological responses early upon neoadjuvant ICB in HNSCC, outperforming the EORTC criteria, although pseudoprogression is seen in neck lymph nodes. [18F]FDG-PET could, upon validation, select HNSCC patients for response-driven treatment adaptation in future trials. TRIAL REGISTRATION: https://www. CLINICALTRIALS: gov/ , NCT03003637, December 28, 2016.
引用
- Vos JL, Zuur CL, Smit LA, et al. [18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2021. PMID: 34957526. doi:10.1007/s00259-021-05610-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。